Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Race Oncology Ltd. ( (AU:RAC) ) has provided an update.
Race Oncology Ltd has received human ethics approval to commence a Phase 1a/b clinical trial for their drug RC220, in combination with osimertinib, targeting non-small cell lung cancer patients with specific epidermal growth factor receptor mutations. This approval marks a significant step for Race Oncology, as it allows them to address unmet medical needs in patients who develop resistance to existing treatments, potentially enhancing their position in the oncology market.
More about Race Oncology Ltd.
Race Oncology Ltd is a biotechnology company focused on developing cancer therapies. The company specializes in creating treatments for patients with specific genetic mutations, particularly in the area of non-small cell lung cancer (NSCLC).
Average Trading Volume: 547,974
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$541.1M
For an in-depth examination of RAC stock, go to TipRanks’ Overview page.